Georgia Medical Cannabis Enrollment Surges Under New Law

Georgia’s medical cannabis program is adding patients faster than at almost any time since legal sales began, as an expanded state law pulls thousands of new registrants onto the rolls within weeks of taking effect.

The number of registered patients has climbed past 40,000 for the first time, reaching more than 41,400, according to Georgia Department of Public Health figures provided to Atlanta NBC affiliate WXIA-TV. That marks a jump of nearly 22 percent since the start of June. About 4,700 people have joined since the reforms took effect on July 1, 2026, when the registry stood at 36,703 — a nearly 13 percent increase in roughly three weeks.

The growth follows the Putting Georgia’s Patients First Act, the overhaul Gov. Brian Kemp signed in May 2026 that broadened both who qualifies for the program and what they can buy. Before July, the program counted about 34,000 patients in a state of more than 11 million residents, one of the lowest participation rates of any U.S. medical marijuana program. The early numbers point to pent-up demand that the old rules had kept in check.

What the expanded law changed

The measure rewrote the core terms of a program Georgia first authorized in 2015 but did not open to in-state sales until 2023. It renamed the state’s “low THC oil” registry as a medical cannabis program and scrapped the 5 percent THC cap that had defined it, replacing that limit with a possession ceiling of 12,000 milligrams of THC. It also cleared patients 21 and older to use vaporized products, though smoking remains banned for everyone. The switch from a percentage cap to a milligram limit also gave patients and physicians a clearer way to gauge dosing, which supporters said had confused participants under the old system.

Just as consequential for enrollment, the law widened the door to the registry. It added qualifying conditions including lupus and inflammatory bowel disease, and it removed the requirement that many diagnoses, among them cancer, multiple sclerosis and Parkinson’s disease, be classified as severe or end-stage before a patient could qualify. Patients still need certification from a state-licensed physician and must register with the Georgia Department of Public Health, renewing that certification each year, to hold a medical cannabis card.

Why the surge matters for operators

Georgia built one of the most tightly controlled cannabis markets in the country, and registry growth now feeds directly into how much retail the state permits. Only six companies hold licenses to grow and process the product, and under state law the Georgia Access to Medical Cannabis Commission can authorize additional dispensing licenses each time enrollment climbs another 10,000 patients past the 25,000 mark. The registry crossed 35,000 as the reforms landed and is now approaching 45,000, opening room for more storefronts in a state that has operated only about 20 dispensaries.

Retail access is widening on a second front: independent pharmacies can now dispense medical cannabis alongside those dispensaries, a shift enabled by the reclassification of state-licensed medical cannabis to Schedule III that took effect in April 2026. For the licensed operators, a rapidly expanding patient base signals a far larger addressable market than the program has ever supported, most of it still concentrated in metro Atlanta.

Georgia is not the only state easing a restrictive medical program this year. Kentucky recently added 15 qualifying conditions to its own program, part of a wider trend of states lowering the barriers to medical access.

What to watch next

Whether the pace holds depends heavily on physicians. Because certification runs through licensed doctors and must be renewed annually, growth will track how quickly the state’s medical community takes up the new authority. Supply is the other open question: a market capped at six producers could strain if enrollment keeps climbing at its current rate, and the Commission is still finalizing testing and packaging standards for the newly permitted vaporized and higher-potency products, so those items are reaching shelves gradually rather than all at once.

Industry operators expect the climb to continue, with some projecting that the patient count could roughly triple within a year as the new products and broader eligibility take hold. For a state that spent a decade running one of the country’s most cautious medical cannabis programs, the coming months will test whether its limited supply can keep up with the demand its own reforms have created.